Enlivex (ENLV) Operating Income (2014 - 2025)
Enlivex (ENLV) posted quarterly Operating Income of -$5.9 million for Q4 2025, down 4.07% year-over-year from -$6.1 million in Q4 2024, and down 129.21% quarter-over-quarter from -$2.6 million in Q3 2025.
Enlivex (ENLV) Operating Income (2014 - 2025) Analysis & Trends
Enlivex's Operating Income history runs 12 years deep, the most recent figure standing at -$5.9 million for Q4 2025.
- In Q4 2025, Operating Income fell 4.07% year-over-year to -$5.9 million; the TTM figure through Dec 2025 stood at -$15.0 million (up 5.41% YoY), while the FY2025 annual figure was -$15.0 million, up 5.41% from the prior year.
- Operating Income for Q4 2025 stood at -$5.9 million, down from -$2.6 million in the prior quarter.
- The five-year high for Operating Income was -$2.6 million in Q3 2025, with the low at -$10.3 million in Q4 2023.
- The 5-year median for Operating Income is -$5.6 million (2023), against an average of -$5.3 million.
- The sharpest annual moves came in 2021 and 2024: Operating Income sank 111.36% in 2021, then soared 55.09% in 2024.
- Enlivex's Operating Income stood at -$7.8 million in 2021, then fell by 0.4% to -$7.8 million in 2022, then sank by 31.74% to -$10.3 million in 2023, then jumped by 45.51% to -$5.6 million in 2024, then dropped by 4.07% to -$5.9 million in 2025.
- Business Quant data shows ENLV's Operating Income at -$5.9 million in Q4 2025, -$2.6 million in Q3 2025, and -$3.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - | -5.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.86 Mn |
| Sep 30, 2025 | -2.56 Mn |
| Jun 30, 2025 | -3.08 Mn |
| Mar 31, 2025 | -3.53 Mn |
| Dec 31, 2024 | -5.63 Mn |
| Sep 30, 2024 | -3.12 Mn |
| Jun 30, 2024 | -2.99 Mn |
| Mar 31, 2024 | -4.15 Mn |
| Dec 31, 2023 | -10.34 Mn |
| Sep 30, 2023 | -5.63 Mn |
| Jun 30, 2023 | -6.65 Mn |
| Mar 31, 2023 | -6.78 Mn |
| Dec 31, 2022 | -7.85 Mn |
| Sep 30, 2022 | -5.68 Mn |
| Jun 30, 2022 | -5.87 Mn |
| Mar 31, 2022 | -6.40 Mn |
| Dec 31, 2021 | -7.81 Mn |
| Sep 30, 2021 | -3.86 Mn |
| Jun 30, 2021 | -3.81 Mn |
| Mar 31, 2021 | -3.80 Mn |